Skip to main content

Table 3 Malaria infection and anaemia at delivery, by treatment groups

From: Sulphadoxine-pyrimethamine plus azithromycin for the prevention of low birthweight in Papua New Guinea: a randomised controlled trial

Outcome ITT analysis PP analysis
  Control Intervention Risk ratio P Control Intervention Risk ratio P
  (SPCQ and placebo) (SPAZ) (95% CI)   (SPCQ and placebo) (SPAZ) (95% CI)  
Peripheral blood (light microscopy)             
  All infections 40/1,022 (3.9) 23/1,023 (2.3) 0.57 (0.35–0.95) 0.029 39/962 (4.1) 22/972 (2.3) 0.56 (0.33–0.93) 0.024
  P. falciparum 29 (2.8) 18 (1.8) 0.62 (0.35–1.11) 0.104 28 (2.9) 17 (1.8) 0.60 (0.33–1.09) 0.090
  P. vivax 11 (1.1) 5 (0.5) 0.45 (0.16–1.30) 0.142 11 (1.1) 5 (0.5) 0.45 (0.16–1.29) 0.127
Placental blood (light microscopy)             
  All infections 29/847 (3.4) 15/841 (1.8) 0.52 (0.28–0.97) 0.035 28/800 (3.5) 14/803 (1.7) 0.50 (0.26–0.94) 0.028
  P. falciparum 25 (3.0) 15 (1.8) 0.60 (0.32–1.14) 0.115 24 (3.0) 14 (1.7) 0.58 (0.30–1.12) 0.098
  P. vivax 1 (0.1) 0 (0.0) 1 (0.1) 0 (0.0)
Cord blood (light microscopy)a 4/744 (0.5) 3/744 (0.4) 0.75 (0.17–3.34) 1.000 4/695 (0.6) 3/716 (0.4) 0.73 (0.16–3.24) 0.681
Placental malaria (histology)             
  Active and past infectionb 150/736 (20.4) 128/736 (17.4) 0.85 (0.69–1.06) 0.143 138/697 (19.8) 122/702 (17.4) 0.88 (0.71–1.10) 0.245
  Active infectionc 65/736 (8.8) 44/736 (6.0) 0.68 (0.47–0.98) 0.037 62/697 (8.9) 41/702 (5.8) 0.66 (0.45–0.96) 0.029
Anaemia (Hb <11 g/dL) 689/935 (73.7) 700/933 (75.0) 1.02 (0.97–1.07) 0.508 647/883 (73.3) 663/889 (74.6) 1.02 (0.96–1.08) 0.532
Severe anaemia (Hb <7 g/dL) 44/935 (4.7) 37/933 (4.0) 0.84 (0.55–1.29) 0.432 39/883 (4.4) 34/889 (3.8) 0.87 (0.55–1.36) 0.531
  1. Data are number (%). P <0.05 marked in bold.
  2. aAll P. falciparum.
  3. bDetection of parasites or malaria pigment.
  4. cDetection of parasites.